Dr. Reddy's price target raised to $53 from $45 at Barclays » 06:3907/3007/30/20
Barclays analyst Balaji…
Barclays analyst Balaji Prasad raised the firm's price target on Dr. Reddy's to $53 from $45 and keeps an Equal Weight rating on the shares following the company's fiscal Q1 results. The company continues to execute well on its strategy of broadening its product portfolio across geographies, Prasad tells investors in a research note.
|Over a week ago|
Amarin announces data from REDUCE-IT REVASC analysis of VASCEPA » 07:1507/2707/27/20
Amarin Corporation announced that data from the REDUCE-IT REVASC analysis, presented as an encore by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, at The American Society for Preventive Cardiology 2020 Virtual Summit on CVD Prevention, showed that administration of 4 g/day of VASCEPA resulted in a significant 34% reduction in first coronary revascularizations versus placebo. Similar reductions of 36% were observed in total, or first and subsequent, revascularizations. In newly presented data, an early coronary revascularization benefit signal was shown in a prespecified exploratory analysis, with sustained statistical significance attained by 11 months. Coronary revascularization procedures, such as stenting and coronary artery bypass grafts, are invasive, carry multiple risks, and can have significant direct and indirect costs. Patients with elevated triglycerides despite statin therapy have increased risk for ischemic events, including coronary revascularizations. These procedures, whether pre-scheduled or performed in an emergency, inevitably result in additional time spent in a healthcare setting. The analyses from the REDUCE-IT trial included several types of coronary revascularization in statin-treated patients with persistently elevated triglycerides, who also had either cardiovascular disease or diabetes and additional cardiovascular risk factors. Prespecified tertiary endpoint analyses showed that times to first revascularization events were significantly reduced by VASCEPA versus placebo across subtypes of intervention, including elective, urgent, and emergent revascularizations, which were reduced by 32%, 34%, and 38%, respectively. In post hoc analyses, VASCEPA significantly reduced percutaneous coronary intervention by 32% and CABG by 39% relative to placebo/ REDUCE-IT was not specifically powered to examine individual cardiovascular endpoints, therefore p-values presented for these revascularization analyses are nominal and exploratory with no adjustment for multiple comparisons. In addition, coronary revascularization as an endpoint can sometimes be considered subjective; however, these endpoints were adjudicated by an independent, blinded clinical endpoint committee. Results from the total coronary revascularization events analyses are consistent across the various recurrent event statistical models and are also consistent with the first coronary revascularization events results. Together, the REDUCE-IT first and total coronary revascularization events results support the robustness and consistency of the clinical benefit of VASCEPA therapy in reducing coronary revascularization. Funding from Amarin was provided to Brigham and Women's Hospital for Dr. Deepak L. Bhatt's work as the REDUCE-IT study chair and global principal investigator.
Dr. Reddy's receives FDA approval for Xeglyze for lice » 15:5607/2407/24/20
Xeglyze is a pediculicide…
Xeglyze is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older, according to a post to the FDA website. Reference Link
CADTH committee recommends reimbursement for Amarin's Vascepa » 16:0107/2007/20/20
The CADTH Canadian Drug…
The CADTH Canadian Drug Expert Committee recommends that icosapent ethyl be reimbursed to reduce the risk of CV events in statin-treated patients with elevated triglycerides, if certain conditions are met, according to a final recommendation document posted to the CADTH site. Icosapent ethyl is marketed under the brand name Vascepa. Reference Link
Dr. Reddy's announces launch of OTC Nicotine Polacrilex Lozenges in U.S. market » 05:2607/1407/14/20
Dr. Reddy's Laboratories announced the launch of Over-the-Counter Nicotine Polacrilex Lozenges, 2 mg and 4 mg, the store brand version of Nicorette Lozenges in the U.S. market. Dr. Reddy's Nicotine Polacrilex Lozenges are available in multiple pack sizes based on consumers' requirements.
|Over a month ago|
Cantor Fitzgerald pharmaceuticals analysts hold analyst/industry conference call » 10:4306/2906/29/20
Pharmaceuticals Analysts, along with Zachary Silbersher, the founding partner of Kroub, Silbersher & Kolmykov (KSK), PLLC, discuss the likelihood that Amarin will win its appeal for Vascepa on an Analyst/Industry conference call to be held on June 29 at 11 am.
Healthcare Financial Management Association to hold a virtual conference » 08:5606/2406/24/20
MTBC, NVZMY, NVS, NVAX, MRK, LOGI, REGN, RDY, FREQ, RCKT, TRVI, CSU, NVO
HFMA 2020 Digital Annual…
HFMA 2020 Digital Annual Conference will be held on June 24. Webcast Link
Notable open interest changes for June 23rd » 08:5506/2306/23/20
AAPL, AMRN, BAC, AAL
Monday's total option volume of 25.5 million contracts resulted in net open interest growth of 4.84 million calls and 3.73 million puts. Apple (AAPL), Amarin (AMRN), Bank of America (BAC) and American Airlines (AAL) saw the greatest growth. Top five new positions opened include 51k Ford (F) Aug-20 6 puts, 27k Amarin (AMRN) Sep-20 7 calls, 22k Amarin (AMRN) Sep-20 10 calls, 20k Amarin (AMRN) Sep-20 6 puts and 20k US Steel (X) Aug-20 7 puts.
Unusual call flow in option market yesterday » 07:3506/2306/23/20
Notable call activity was…
Notable call activity was cited Monday in US Steel (X) and Amarin (AMRN).
Double spread collar in Amarin opens bullish position » 12:0006/2206/22/20
Double spread collar in…
Double spread collar in Amarin opens bullish position. Shares little changed this morning near $6.80 with a 4-way spread on the ISE where a customer appears to have sold the Sep 5/6 put spread to buy the Sep 7/10 call spread a total of 20k times, opening on all legs. For the largest tranche of 15k, the net credit on the put spread was 27c and the debit on the call spread 77c, for a net debit of 50c, or about $1M on the package. Net delta on the package is nearly 670k shares, or 9% the average daily turnover in the name. Amarin shares dropped nearly 70% from over $13 to $4 on March 31 related to a court ruling. Today's trade could return a 500% gain to the buyer if shares were to return to double digit territory over the next three months.